Most Popular Brands: Lyrica
Pregabalin is an analgesic and anti-convulsant drug that is used to manage pain associated with diabetic peripheral neuropathy, postherpetic (shingles) neuralgia, as an adjunctive treatment for partial-onset seizure disorder in adults and for the management of fibromyalgia.
| Reasons taken | # of patients | Major | Moderate | Slight | None | Can’t tell | # of patients evaluated by |
|---|---|---|---|---|---|---|---|
| Fibromyalgia | 437 |
|
|
|
|
|
145 |
| Pain | 76 |
|
|
|
|
|
37 |
| Nerve pain (neuropathic pain) | 61 |
|
|
|
|
|
19 |
| Muscle Pain | 21 |
|
|
|
|
7 | |
| Other | 19 |
|
|
|
6 | ||
| leg pain at all times | 16 |
|
|
|
5 |
See all 610 patients currently taking Pregabalin
Mouse over the table for more information
Top 10 dosages based on patients currently taking Pregabalin. See all 29 dosages ►
| 100 mg all the time (24/7) | 100 mg as needed | 100mg as needed | 150 mg as needed | 25mg as needed | 3 50mg as needed | 50 mg all the time (24/7) | 50mg as needed | 75 mg all the time (24/7) | 75mg as needed | 25 mg daily | 1000 mg monthly | 50 mg daily | 75 mg daily | 100 mg daily | 100 mg one time | 150 mg daily | 200 mg daily | 225 mg daily | 250 mg daily | 300 mg daily | 350 mg daily | 375 mg daily | 400 mg daily | 450 mg daily | 500 mg daily | 550 mg daily | 600 mg daily | 900 mg daily | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
4
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
1
|
1
|
20
|
1
|
49
|
43
|
53
|
1
|
133
|
35
|
44
|
3
|
141
|
1
|
2
|
15
|
54
|
1
|
1
|
32
|
3
|
||
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
|
Side effects too severe
|
89 | 59% |
|
|
Did not seem to work
|
45 | 30% |
|
|
Expense
|
18 | 12% |
|
|
Doctor's advice
|
16 | 11% |
|
|
Other
|
12 | 8% |
|
|
Personal research
|
6 | 4% |
|
|
Course of treatment ended
|
1 | 1% |
|
|
Not indicated
|
1 | 1% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on November 24, 2009.